We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other blue chip stocks to invest in at 52-week lows.
For the first time since 2023, the S&P 500 was seen in the market correction territory, according to US Bank (Wealth Management). The rapid fall surprised several investors, mainly considering the favorable underlying conditions US stocks carried into 2025. The broader markets are reacting primarily to the potential economic consequences of the Trump administration’s policies. Most critical are the new trade policies focused on raising tariffs for goods imported to the US. According to Rob Haworth, senior investment strategy director with U.S. Bank Asset Management, the uncertainty remains the key driver around the market’s recent decline. There are increased concerns related to the potential economic weakness, mainly because of tariff impacts.
Sector Performance in 2025
As per US Bank (Wealth Management), in 2023 and 2024, stocks were aided by consistent economic growth as technology stocks dominated the broader market performance. The revenues of technology companies were aided by significant spending on AI-related investment. As per Haworth, it is of utmost importance for other sectors to make increased earnings contributions. In the early months of 2025, there was a shift in investor sentiment. The sectors that supported the prior year’s market performance, i.e., IT, communication services, and consumer discretionary, have been dragging the market down.
US Bank (Wealth Management) stated that the markets fluctuated through most of Q1 2025. That being said, by February 19, the S&P 500 gained 4.5%, says the firm. Furthermore, the firm added that YTD through March 17, the broader S&P 500’s total return was down 3.23%. This comes after 2 years of 25%+ S&P 500 total returns. Despite the uncertainty, for the time being, many underlying fundamentals remain positive. According to Eric Freedman, chief investment officer for U.S. Bank Asset Management, the consumers remain in a good spot, and companies are flush with cash.
As per Haworth, while US markets were impacted in Q1 2025, global stocks delivered positive returns. In the current environment, Haworth believes that a globally diversified portfolio places the investors in a position to capitalize on numerous opportunities. Notably, investors tend to respond to the perceived potential corporate earnings based on specific policies or events. Even though there have been struggles in early 2025, most of the underlying data is favorable.
Our Methodology
To list the 11 Blue Chip Stocks to Invest in at 52-Week Lows, we sifted through the holdings of SPDR S&P 500 ETF Trust and shortlisted the stocks trading close to their respective 52-week lows. Next, we mentioned hedge fund sentiments around each stock, as of Q4 2024. Finally, the stocks were arranged in ascending order of their hedge fund sentiments.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Pfizer Inc. (PFE): Among Blue Chip Stocks to Invest in at 52-Week Lows
A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution.
Pfizer Inc. (NYSE:PFE) is engaged in discovering, developing, manufacturing, marketing, distributing, and selling biopharmaceutical products. The company remains focused on improving the productivity of its R&D pipeline and advancing the clear strategic priorities in 2025. Pfizer Inc. (NYSE:PFE) made significant progress with the commercial execution as well as achieved growth throughout its product portfolio for FY 2024, which includes $3.4 billion in revenue from its legacy Seagen portfolio, and healthy growth from the Vyndagel family, Eliquis, Xtandi, Nurtec, and several other products throughout all categories.
Pfizer Inc. (NYSE:PFE) saw 12% operational revenue growth of its non-COVID products in FY 2024, demonstrating its continued focus on commercial execution. The company has delivered on its $4 billion net cost savings target from the ongoing cost realignment program and has increased its overall savings target to ~$4.5 billion by the end of the year. Overall, strong commercial execution and global presence are expected to act as potential tailwinds. Pfizer Inc. (NYSE:PFE)’s global commercial infrastructure could be used to maximize the potential of Seagen’s approved products and pipeline candidates, resulting in the acceleration of market penetration and revenue growth. Also, the addition of Seagen’s products and pipeline supports the company in diversifying the revenue base, reducing the dependency on any single product or therapeutic area.
Overall, PFE ranks 1st on our list of blue chip stocks to invest in at 52-week lows. While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a deeply undervalued AI stock that is more promising than PFE but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
